Index to Volume 1: Subject

Abomasum, vagal influences of, 15
Acetylcholine release, 76(ab)
Actin mRNA expression, in intestinal smooth muscle, 61(ab)
Adenosine, 71(ab), 77(ab)
Adenosine nucleotides, 71(ab)
Adrenaline, 59(ab)
Adrenergic receptor antagonists, ileal brake mechanism and, 44(ab)
Adrenoceptor agonists, 55(ab)
Alvarez, Walter, 2–3
Amiloride, 50(ab)
Anorexia nervosa, 77(ab)
Anti-cholinesterase, 57(ab)
Antropyloric motility, duodenogastric reflex and, 49(ab)
Antrum, gastric
  circular muscle layer of, 69(ab)
  distention, postoperative pacing for, 66(ab)
  dysrhythmias, 53(ab)
  smooth muscle of, 48(ab)
Auerbach's plexus, 51(ab)

Baboon
  gastric antrum, electrical activity in, 69(ab)
  small intestine, neuromuscular transmission in, 68(ab)
Barostat measurement, of gallbladder wall tone, 51(ab)
Benzamides, 79(ab)
Bethanechol, colonic motility and, 29–33
Bile acids, MMC and, 67(ab)
Bile salts, gallbladder contractivity and, 70(ab)
Blood pressure
  ritodrine and, 47(ab)
  SR 58611A and, 47(ab)
Body weight, in primary anorexia nervosa, 77(ab)
Bombesin, effect on myoelectrical activity of canine GI tract, 76(ab)
Brain-gut interaction, 5–8
Brainstem viral-like encephalitis, gastroduodenal motility disorder and, 99–102
N-Buthylscopolamine, 45(ab)

Calcitonin gene-related peptide, 67(ab)
Calcium
  motilide-induced contractions and, 47(ab)
  sensitivity, age-related and regional differences for rat colon force development, 73(ab)
Calcium channel agonists, 50(ab)
Canine model
  colonic motility, 65(ab)
  ileal circular muscle motility, 63(ab)
  intestinal migrating motor complex induction, 58(ab)
  jejunal myoelectric activity, hookworm infestation and, 78(ab)
  mesenteric ganglionectromy in, 49(ab)
  oubain-induced depolarization in smooth muscle, 64(ab)
  prokinetic benzamides in, 79(ab)
  small intestinal contractions, 54(ab)
  small intestine motility, 64(ab)
  terminal ileum, regulation of rapid mechanical activity, 74(ab)
  upper esophageal sphincter contraction and swallowing, 68(ab)
Cannon, Walter, 2
Capsaicin-sensitive vagal pathways, 52(ab)
CCK-8. *See* Cholecystokinin octapeptide
CCK (cholecystokinin), 73(ab)
CHAOS techniques, 44(ab), 71(ab)
Cholecystokinin-antagonist, 61(ab)
Cholecystokinin (CCK), endogenous, gastric emptying and, 73(ab)
Cholecystokinin octapeptide (CCK-8)
  effect on gastro-duodenal vagal afferent fibre, 63(ab)
  gastric motility and, 54(ab)
Choledochoduodenal junction, propulsive activity of, 115–120
Circular muscle
  spontaneous electrical activity in, 69(ab)
  submucosal motor innervation of, 53(ab)
Cisapride, 46(ab), 52(ab), 77(ab)
Cisplatin, gastric emptying in rat and, 52(ab)
Clonidine
  colonic transit and, 49(ab), 85–88
Colitis, induced, 75(ab)
Colon
  muscular interactions in, 51(ab)
  proximal, myoelectrical activity of, 47(ab)
Colonic contractions
  circadian and diurnal aspects of, 75(ab)
  mucosal inflammation and, 69(ab)
Colonic distension, acetylcholine release and, 76(ab)
Colonic motility
  intraluminal pressure recording technique for, 60(ab)
  mechanoreceptors in, 79(ab)
  mesenteric ganglionectomy and, 49(ab)
  postprandial, trimebutine and, 9–13
  regional differences in, 29–33
Colonic myocytes, 64(ab), 74(ab)
Colonic transit
  alpha-$_2$ adrenergics and, 85–88
  alpha-$_2$, 85–88
  noninvasive quantification of, 75(ab)
  noninvasive radionuclide assessment of, 62(ab)
Congenital idiopathic intestinal pseudo-obstruction, 53(ab)
Connective tissue diseases, 75(ab)
Constipation, chronic
  after learning normal defecation patterns, 69(ab)
  idiopathic, 44(ab)
Corticotropin-releasing factor (CRF)
  colonic motility and, 58(ab)
  in gastroduodenal motility, 80(ab)
  TRH release and, 48(ab)
CR1409, 52(ab)
CRF (corticotropin-releasing factor), 48(ab), 58(ab), 80(ab)
Crohn's disease, 65(ab)
Crural diaphragm, 46(ab)
Cyproheptadine, 131

Diabetes mellitus, VIP release and, 56(ab)
Diarrhea
  cholera toxin and, 90–97
  relationship of small intestine motility and transit, 50(ab)
Domperidone, 52(ab)
Duodenogastric reflux
  antropyloric motility and, 49(ab)
  detection of, 62(ab)
Duodenum, motor complexes of, 7–8
Dye-coupling, 70(ab)
Dynorphin, 57(ab), 68(ab)
Dysrhythmias, gastric, 53(ab)

ECP (eosinophil cationic protein), 55(ab)
Electrogastrography, in gastric ulcer patients, 122–129
EM-523, 47(ab)
Encephalitis, gastroduodenal motility disorder and, 99–102
Encopresis, chronic, 69(ab)
Enteric nervous system, 50(ab), 144
Eosinophil cationic protein (ECP), 55(ab)
Eosinophils, esophageal achalasia and, 55(ab)
ERCP, 45(ab)
Erythromycin, 46(ab)
Erythromycin derivatives, 150–158
Esophageal achalasia, 55(ab)
Esophageal acid clearance, in reflux esophagitis, 105–113
Esophageal body, primary peristalsis and, 48(ab)
Esophageal contractions, giant, 49(ab)
Esophageal manometry
  digital ambulatory and long-term, in determination of normal values, 59(ab)

Index to Volume 1: Subject

Abomasum, vagal influences of, 15
Acetylcholine release, 76(ab)
Actin mRNA expression, in intestinal smooth muscle, 61(ab)
Adenosine, 71(ab), 77(ab)
Adenosine nucleotides, 71(ab)
Adrenaline, 59(ab)
Adrenergic receptor antagonists, ileal brake mechanism and, 44(ab)
Adrenoceptor agonists, 55(ab)
Alvarez, Walter, 2–3
Amiloride, 50(ab)
Anorexia nervosa, 77(ab)
Anti-cholinesterase, 57(ab)
Antropyloric motility, duodenogastric reflex and, 49(ab)
Antrum, gastric
  circular muscle layer of, 69(ab)
  distention, postoperative pacing for, 66(ab)
  dysrhythmias, 53(ab)
  smooth muscle of, 48(ab)
Auerbach's plexus, 51(ab)

Baboon
  gastric antrum, electrical activity in, 69(ab)
  small intestine, neuromuscular transmission in, 68(ab)
Barostat measurement, of gallbladder wall tone, 51(ab)
Benzamides, 79(ab)
Bethanechol, colonic motility and, 29–33
Bile acids, MMC and, 67(ab)
Bile salts, gallbladder contractivity and, 70(ab)
Blood pressure
  ritodrine and, 47(ab)
  SR 58611A and, 47(ab)
Body weight, in primary anorexia nervosa, 77(ab)
Bombesin, effect on myoelectrical activity of canine GI tract, 76(ab)
Brain-gut interaction, 5–8
Brainstem viral-like encephalitis, gastroduodenal motility disorder and, 99–102
N-Buthylscopolamine, 45(ab)

Calcitonin gene-related peptide, 67(ab)
Calcium
  motilide-induced contractions and, 47(ab)
  sensitivity, age-related and regional differences for rat colon force development, 73(ab)
Calcium channel agonists, 50(ab)
Canine model
  colonic motility, 65(ab)
  ileal circular muscle motility, 63(ab)
  intestinal migrating motor complex induction, 58(ab)
  jejunal myoelectric activity, hookworm infestation and, 78(ab)
  mesenteric ganglionectromy in, 49(ab)
  oubain-induced depolarization in smooth muscle, 64(ab)
  prokinetic benzamides in, 79(ab)
  small intestinal contractions, 54(ab)
  small intestine motility, 64(ab)
  terminal ileum, regulation of rapid mechanical activity, 74(ab)
  upper esophageal sphincter contraction and swallowing, 68(ab)
Cannon, Walter, 2
Capsaicin-sensitive vagal pathways, 52(ab)
CCK-8. *See* Cholecystokinin octapeptide
CCK (cholecystokinin), 73(ab)
CHAOS techniques, 44(ab), 71(ab)
Cholecystokinin-antagonist, 61(ab)
Cholecystokinin (CCK), endogenous, gastric emptying and, 73(ab)
Cholecystokinin octapeptide (CCK-8)
  effect on gastro-duodenal vagal afferent fibre, 63(ab)
  gastric motility and, 54(ab)
Choledochoduodenal junction, propulsive activity of, 115–120
Circular muscle
  spontaneous electrical activity in, 69(ab)
  submucosal motor innervation of, 53(ab)
Cisapride, 46(ab), 52(ab), 77(ab)
Cisplatin, gastric emptying in rat and, 52(ab)
Clonidine
  colonic transit and, 49(ab), 85–88
Colitis, induced, 75(ab)
Colon
  muscular interactions in, 51(ab)
  proximal, myoelectrical activity of, 47(ab)
Colonic contractions
  circadian and diurnal aspects of, 75(ab)
  mucosal inflammation and, 69(ab)
Colonic distension, acetylcholine release and, 76(ab)
Colonic motility
  intraluminal pressure recording technique for, 60(ab)
  mechanoreceptors in, 79(ab)
  mesenteric ganglionectomy and, 49(ab)
  postprandial, trimebutine and, 9–13
  regional differences in, 29–33
Colonic myocytes, 64(ab), 74(ab)
Colonic transit
  alpha-$_2$ adrenergics and, 85–88
  alpha-$_2$, 85–88
  noninvasive quantification of, 75(ab)
  noninvasive radionuclide assessment of, 62(ab)
Congenital idiopathic intestinal pseudo-obstruction, 53(ab)
Connective tissue diseases, 75(ab)
Constipation, chronic
  after learning normal defecation patterns, 69(ab)
  idiopathic, 44(ab)
Corticotropin-releasing factor (CRF)
  colonic motility and, 58(ab)
  in gastroduodenal motility, 80(ab)
  TRH release and, 48(ab)
CR1409, 52(ab)
CRF (corticotropin-releasing factor), 48(ab), 58(ab), 80(ab)
Crohn's disease, 65(ab)
Crural diaphragm, 46(ab)
Cyproheptadine, 131

Diabetes mellitus, VIP release and, 56(ab)
Diarrhea
  cholera toxin and, 90–97
  relationship of small intestine motility and transit, 50(ab)
Domperidone, 52(ab)
Duodenogastric reflux
  antropyloric motility and, 49(ab)
  detection of, 62(ab)
Duodenum, motor complexes of, 7–8
Dye-coupling, 70(ab)
Dynorphin, 57(ab), 68(ab)
Dysrhythmias, gastric, 53(ab)

ECP (eosinophil cationic protein), 55(ab)
Electrogastrography, in gastric ulcer patients, 122–129
EM-523, 47(ab)
Encephalitis, gastroduodenal motility disorder and, 99–102
Encopresis, chronic, 69(ab)
Enteric nervous system, 50(ab), 144
Eosinophil cationic protein (ECP), 55(ab)
Eosinophils, esophageal achalasia and, 55(ab)
ERCP, 45(ab)
Erythromycin, 46(ab)
Erythromycin derivatives, 150–158
Esophageal achalasia, 55(ab)
Esophageal acid clearance, in reflux esophagitis, 105–113
Esophageal body, primary peristalsis and, 48(ab)
Esophageal contractions, giant, 49(ab)
Esophageal manometry
  digital ambulatory and long-term, in determination of normal values, 59(ab)

in esophageal motility disorder assessment, 68(ab)
with pH-monitoring in newborns, infants and children, 59(ab)
vs. automatic analysis, 21–27
Esophageal motility, automatic vs. manual analysis, 21–27
Esophageal motility disorders, 68(ab)
Esophageal peristalsis, hyperventilation and, 76(ab)
Esophageal pressures
in non-cardiac chest pain, 69(ab)
during upright liquid and solid swallows, 67(ab)
Esophagogastric junction, in esophageal achalasia, 55(ab)
Esophagus
hypertrophic smooth muscle of, 56(ab)
motor activity, 75(ab)
postdeglutitive motor activity, automatic analysis of, 21–27
Excitatory postsynaptic potentials, 66(ab)

Feline model
colonic transit, alpha-2 receptor mediation of, 49(ab)
esophagus, vagal efferents of, 68(ab)
gallbladder, inhibitory innervation of, 78(ab)
intestinal NK-1 and NK-2 receptors, 72(ab)
Fundic gastric smooth muscle, 48(ab)

Galanin, 73(ab)
Gallbladder
calcitonin gene-related peptide and, 67(ab)
contractivity, bile salts and, 70(ab)
motility in dogs, PYY and, 44(ab)
wall tone, 51(ab)
Ganglionic transmission mechanisms, in naloxone-sensitive NANC jejunal contractions, 65(ab)
Gastric corpus relaxation, 63(ab)
Gastric dysrhythmias, and vasopressinergic pathways during vection-induced nausea, 53(ab)
Gastric electrical control activity, 71(ab)
Gastric emptying
central vs. peripheral administration of serotonin agonists, 52(ab)
endogenous CCK and, 73(ab)
erythromycin and, 46(ab)
5-HTantagonists and, 54(ab)
in primary anorexia nervosa, 77(ab)
stress-induced, 48(ab)
Gastric motility
phasic contractile activity
serotonin and, 131–136
Gastric motor activity, histamine H_2-receptor antagonists and, 57(ab)
Gastric myenteric plexus, serotonergic mechanisms in, 56(ab)
Gastric oscillators, 44(ab)
Gastric relaxation, 63(ab)
Gastric tone, of ruminant true stomach, 15–20
Gastric ulcer, electrogastrography of, 122–129
Gastrocolonic response, 61(ab)
Gastroduodenal motility, corticotropin releasing factor and, 80(ab)
Gastroduodenal motility disorder, brainstem viral-like encephalitis and, 99–102
Gastroesophageal reflux
acid exposure times and, 59(ab)
in reflux esophagitis, 105–113
Gastrointestinal motility
polyamines and, 53(ab)
rectal motor complex and, 5–8
Gastrointestinal motor activity, in motion sickness, 54(ab)
Gastrokinetic agents, 150–158
Gastroparesis, 79(ab)
Giant migrating contractions
cholera toxin and, 90–97
enteric neural control of, 50(ab)
Glottic-closure, deglutitive, 62(ab)
Granisetron, 54(ab)
Guanethidine, NPY-induced quiescence of migrating myoelectric complex and, 38
Guinea pig
choledochoduodenal junction, 115–120
colonic mechanoreceptors, 77(ab)
ileum, 71(ab)
internal anal sphincter, 58(ab)
myenteric plexus, 56(ab), 65(ab)
rectum, myenteric neurons in, 72(ab)
small intestine, peristaltic motor activity in, 144–148

Heart rate
ritodrine and, 47(ab)
SR 58611A and, 47(ab)
Histamine H-receptor antagonists, 57(ab)
Hookworm infestation, canine jejunal myoelectric activity and, 78(ab)
$5HT_3$ antagonists
gastric emptying and, 54(ab)
in gastroparesis, 79(ab)
5-Hydroxytryptamine. *See* Serotonin
Hyperventilation, esophageal peristalsis and, 76(ab)

Idiopathic hypertrophic pyloric stenosis, 76(ab)
Ileal brake mechanism, 44(ab)
Ileal emptying, 75(ab)
Ileo-cecal valve, 48(ab)
Infants, small intestinal motility in, 138–143
Insulin, 79(ab)
Interstitial cells of Cajal
electrical activity of, 64(ab), 74(ab)
identification by scanning electron microscopy, 52(ab)
ultrastructure of, 51(ab)
visualization of, 73(ab)
Interstitial muscle, 65(ab)
Intrinsic intestinal nerves, 115–120
Irritable bowel syndrome
corticotropin releasing factor and, 58(ab)
motility in, trimebutine and, 9–13
sleep and, 66(ab)

Kappa-opioid receptors, 57(ab)

LES. *See* Lower esophageal sphincter
Leukotrienes, 72(ab)
Leu^{13}-psi-(CH_2NH-Leu^{14})-bombesin, 67(ab)
Loperamide, small intestinal myoelectric activity and, 70(ab)
Lower esophageal sphincter (LES)
agonist-induced contractions of, galanin and, 73(ab)
feline, second messengers in VIP-mediated relaxation of, 78(ab)
pressure, rioprostil and, 23–24
transient relaxations, 46(ab), 62(ab), 105
Loxiglumide, 61(ab)

Macrolides, structure and motility effects, 150–158
Mast cells, 65(ab)
Mesenteric ganglionectomy
colonic motility and, 49(ab)
transit disturbances and, 49(ab)
Met-enkephalin, 68(ab)
Methysergide, 131
Migrating clustered contractions, 90–97
Migrating motor complex. *See* Migrating myoelectric complex (MMC)
Migrating myoelectric complex (MMC)
cholera toxin and, 90–97
definition of, 5
enterohepatic circulation of bile acids and, 67(ab)
in germ free rats, 60(ab)
motilin release and, 60(ab)
neuropeptide-Y and, 35–40
phase III, 45(ab)
refractory period of, 45(ab)
Motilides, 47(ab), 150–158
Motilin, 60(ab), 150–158
Motilin receptor density, 47(ab)
Motion sickness, 54(ab)
Myenteric plexus
extrinsic nerves in, 72(ab)
ganglia, dye-coupling in, 70(ab)

Myoelectric activity
after thoracic vagotomy in sheep, 17
and intrinsic fluid-propelling behavior in cat jejunum, 61(ab)
in motion sickness, 54(ab)
of small intestine, neuropeptide Y and, 35–40
Myosine distribution, in feline upper gastrointestinal tract, 77(ab)

Naloxone, NPY-induced quiescence of MMC and, 38
Naloxone-sensitive, NANC jejunal contractions, 65(ab)
Nausea, in gastric ulcer, 122–129
Neurokinin A, 44(ab)
Neuropeptide Y, small intestinal motility and, 35–40
Neurotensin receptors, 64(ab)
Neurotransmitter/neuromodulator functions, of GRP in porcine antrum, 67(ab)
NK-1 receptors, 72(ab)
NK-2 receptors, 72(ab)
Noradrenaline, pyloric smooth muscle response and, 59(ab)
Nutcracker esophagus, 49(ab)

Opiate receptor antagonists, ileal brake mechanism and, 44(ab)
Opossum esophagus
extrinsic nerves in myenteric plexus of, 72(ab)
muscularis mucosae, substance P release from capasaicin-sensitive nerves, 63(ab)
peristalsis in, 57(ab)
Oropharyngeal swallowing, coordination and timing of, 62(ab)

Pacemaker activity, in canine colon, 64(ab)
Pancreatobiliary juice, 60(ab)
Peptide YY, 44(ab)
Peristalsis
esophageal, hyperventilation and, 76(ab)
in opossum smooth-muscle esophagus, 57(ab)
thyrotropin-releasing hormone and, 144–148
Peristaltic reflex, neural circuitry of, 71(ab)
Pervertebral sympathetic ganglia, dye-coupling in, 70(ab)
pH, in non-cardiac chest pain, 69(ab)
Phentolamine, NPY-induced quiescence of MMC and, 38
Platelet-activating factor, 58(ab)
Polyamines, gastrointestinal motility and, 53(ab)
Post-cholecistectomy pain syndrome, 46(ab)
Postoperative ileus, stomach and, 66(ab)
Postoperative pacing, for gastric antral distention, 66(ab)
Potassium, 64(ab)
Potassium chloride, effect on proximal and distal colonic motility, 29–33
Potassium ion channels, Ca^{2+}-activated muscarinic supression, in colonic myocytes, 74(ab)
repolarization of gastric slow waves, 74(ab)
Prazosin, colonic transit in rats and, 85–88
Primary peristalsis, prolonged acidification and, 48(ab)
Propranolol, NPY-induced quiescence of MMC and, 38
Prostaglandin E analogs
esophageal motility and, 21–27
migrating myoelectric complex induction and, 58(ab)
Prostaglandin H synthase, 51(ab)
Prostaglandins, 58(ab)
Psychic stress, colonic motor alterations in, 58(ab)
Purines, effects on NANC-nerve mediated IJP, 71(ab)
Pyloric motor function, central and peripheral peptidergic regulation of, 50(ab)
Pyloric stenosis, 15, 76(ab)
Pylorus
electrophysiology, in idiopathic hypertrophic pyloric stenosis, 76(ab)
second messengers in VIP-mediated relaxation of, 78(ab)

Rabbit, motilin receptor density in, 47(ab)
Rabbits
gastric smooth muscle, tachykinin receptors of, 78(ab)
Radiology, in esophageal motility disorder assessment, 68(ab)
Rats
CCK8 neurons of ventromedial hypothalamus, 54(ab)
endotoxin-induced intestinal motor disturbances in, 58(ab)
germ free, MMC in, 60(ab)
pyloric motor function, central and peripheral peptidergic regulation of, 50(ab)
Rectal motility, 5–8
Rectal motor complex, 5–8
Reflux esophagitis, spontaneous gastroesophageal reflux and esophageal acid clearance in, 105–113
Reticulorumen, 15
Retrograde giant contraction, 90–98
Rhodamine 123, 73(ab)
Ricin-induced enteric inflammation, 72(ab)
Rioprostil, human esophageal motility and, 21–27
Ritodrine, 47(ab)
RU749, gastric emptying and, 60(ab)
Ruminant true stomach. *See* Abomasum
Running spectrum analysis, in gastric ulcer, 122–129

Scanning electron microscopy, of interstitial cells of Cajal, 52(ab)
Serotonin, 46(ab)
canine terminal ileum and ileocolonic junction and, 56(ab)
effect on gastrointestinal contractile activity in conscious dogs, 131–136
Serotonin agonists, 52(ab)
Serotonin receptor antagonists, gastrointesinal motor activity and, 55(ab)
Sigmoid colon, intrinsic innervation of, 44(ab)
Sleep, irritable bowel and, 66(ab)
Slow wave period, 45(ab)
Slow wave propagation velocity, 79(ab)
Small intestine
calcitonin gene-related peptide and, 67(ab)
effects of diabetes mellitus on VIP release, 56(ab)
localization of prostaglandin H synthase, 51(ab)
neuromuscular transmission in, 68(ab)
spike burst patterns in, 45(ab)
transit time, 45(ab)
Small intestine motility
maturation of, 138–143
neuropeptide Y and, 35–40
PYY and, 44(ab)
Small intestine motor activity
in fasted state, cholera toxin and, 90–97
transit in normal state and diarrhea, 50(ab)
Small intestine myoelectric activity, loperamide and, 70(ab)
Smooth muscle cells
in pacemaker activity of canine colon, 64(ab)
in small intestine, dye-coupling in, 70(ab)
Smooth muscle relaxation, cyclic nucleotides and, 58(ab)
Sodium, 62(ab), 64(ab)
Sphincter of Oddi, 115–120
motility, 45(ab)
in post-cholecistectomy pain syndrome, 46(ab)
Splanchnic nerve fiber system, 71(ab)

SR 58611A, 47(ab)
St-91, colonic transit in rats and, 85–88
Stomach, postoperative ileus and, 66(ab)
Stress
  gastric emptying and, 48
  gastroduodenal motility and, 80(ab)
Submuscular plexus, interstitial cells of Cajal, 51(ab)
Substance P, 45(ab), 63(ab)

Tachykinins, 65(ab)
Tetrodotoxin, 57(ab)
Thyrotropin-releasing hormone (TRH)
  peristaltic motor activity in guinea pig small intestine and, 144–1448
  release, 48(ab)
Tifluadom, 57(ab)
Transit, intestinal
  neuropeptide Y and, 35–40
  in normal state and diarrhea, 50(ab)
Trimebutine
  colonic mechanoreceptor inputs to inferior mesenteric ganglion and, 66(ab)
  postprandial colonic motor activity and, 9–13

U 50–488, 57(ab)
U 69–593, 57(ab)
Upper esophageal sphincter, biomechanics of, 57(ab)

Vagal cooling, effect on gastric tone in ovine stomach, 15–20
Vagal nerve fiber system, 71(ab)
Vagotomy, effect on gastric motility in ovine stomach, 15–20
Vagovagal reflexes, in ovine stomach, 15–20
Vagus nerves, in relaxation of gastric corpus, 63(ab)
Vasoactive intestinal polypeptide (VIP), 56(ab), 63(ab)
Ventromedial hypothalamus, CCK8 neurons of, 54(ab)
Vomiting, in gastric ulcer, 122–129

Yohimbine, colonic transit in rats and, 85–88

Zacopride, 52(ab)

Index to Volume 1: Author

Abatzi, Th.-A., 77
Abell, T.L., 138
Aggestrup, S., 55
Ahmad, S., 64
Alampi, G., 99
Allescher, H.-D., 45
Amarnath, R.P., 138
Andersson, K.-E., 55
Angel, F., 44
Annese, V., 46
Anthony, T.L., 77
Arndorfer, R.C., 62, 105

Bailey, H., 73
Baird, A.A., 58
Baluk, P., 70
Barajas-Lopez, C., 64
Barbara, L., 46, 99
Barber, W.D., 71
Barberani, F., 48
Bardakjian, B.L., 44
Barnett, T.G., 65
Bass, P., 53
Bauer, A.J., 68, 69
Behar, J., 78
Berezin, I., 64
Bergeron, R.J., 53
Bergmann, H., 77
Berseth, C.L., 138
Biancani, P., 78
Bianchetti, A., 47
Bianchi, R.G., 79
Binder, A., 75
Bingaman, S., 53
Bird, N.C., 62
Bisset, W.M., 53
Blackshaw, L.A., 63
Blum, A.L., 59
Boeckxstaens, G.E., 56
Bonfilio, A.C., 52
Bontempo, I., 48
Bornstein, J.C., 71
Bortoff, A., 79
Bortolotti, M., 46, 99
Boveri, S., 47
Bowes, K.L., 49, 51
Brancheк, T.R., 79
Braquet, P., 58
Brikas, P., 55
Bro, S.L., 57
Broad, R.M., 65
Brocchi, E., 46
Brown, D., 49
Brown, N.J., 44
Brugere, H., 49
Bruley, S., 73
Bueno, L., 48, 54, 55, 58, 85
Buhner, S., 54
Bumm, R., 59
Burakoff, R., 75
Burke, D.G., 44
Burke, E.P., 73
Burks, T.F., 71
Burrows, C.F., 78
Burton, M.B., 75
Butsch, B.H., 61
Butt, W.G., 73
Bywater, R.A.R., 115
Cachet, T., 150
Caenepeel, Ph., 45
Calabuig, R., 61
Caletti, G.C., 46
Caliezi, A., 57
Camilleri, M., 75
Carl, A., 74
Castell, D.O., 67, 68
Castell, J., 67
Castiglione, F., 59
Chang, T.M., 56
Chase, B.J., 49
Chaussade, S., 49
Chen, Y.M., 68
Cheskin, L.J., 75
Chey, W.Y., 56
Chow, E., 64
Christensen, J., 72
Christofi, F.L., 77
Cilluffo, T., 59
Classen, M., 45
Cockel, R., 76
Code, C.F., 3
Cohen, S., 73
Cole, E., 76
Cole, W.C., 74
Collins, S.M., 9, 65
Collman, P.I., 68
Cominelli, F., 69
Condon, R.E., 70
Cook, I.J., 9
Cook, M.A., 65
Corazziari, E., 48
Courtney, T., 66
Couturier, D., 49
Cowles, V.E., 50, 90
Coy, D.H., 67
Croci, T., 47
Crowell, M.D., 75
Cuccurullo, F., 45
Curran, P., 73
Cypris, S., 63

Dahl, R., 55
Dalton, C.B., 68
Daniel, E.E., 63, 64
Dantas, R.O., 62
Davis, E.L., 61
De Bondt, F., 21
Deinsberger, R., 59
Dekker, W., 69
Delbro, D., 65
Delle Fave, G., 48
Delvaux, M., 58
De Man, J.G., 56
Dent, J., 50, 105
Depoortere, I., 47, 150
Devane, S.P., 53
Diamant, N.E., 44, 68
Didier, E., 44
Dimitri, A., 45
Diop, L., 48

Ditlev Hansen, E., 51
Dodds, W.J., 57, 62, 105
Domschke, W., 44
Dorsett, J.A., 67
Drack, E., 57
Droy-Lefaix, M.T., 58
Du, C., 56
Dubois, A., 73
Duphar, B.V., 52

Eeckhout, C., 52
Ehrlein, H.J., 54
El-amir, N., 79
Elder-Oey, L., 73
Emde, C., 59
Enck, P., 61
Erckenbrecht, J.F., 61
Eysselin, V.E., 69

Ferre, J.P., 49
Fich, A., 74
Fiebig, M., 74
Fioramonti, J., 55, 58, 85
Fisher, M., 46
Fisher, R.S., 49
Flourie, B., 60
Forman, A., 55
Fouquet, G., 56
Fox, J.E.T., 63
Franchisseur, C., 60
Fredens, K., 55
Freidin, N., 62
French, S., 44
Frexinos, J., 58
Fujimura, M., 57
Funch-Jensen, P., 55
Furness, J.B., 71

Gamse, R., 54
Garcia, F., 72
Gaupmann, G., 75, 77
Geldof, H., 122
Gershon, M.D., 79
Gharib Naseri, M.K., 63
Giangaspero, G., 99
Giudice, A., 47
Golenhofen, K., 59
Gonklin, J., 56
Granser, G., 75
Grashuis, J.L., 122
Greiner, E.C., 78
Grenier, J.F., 44
Grossi, L., 45
Grundy, D., 63
Grundy, D.G., 1
Gue, M., 48, 58
Guerre, J., 49
Guild, S.B., 58
Gullikson, G.W., 79
Gustafsson, B.I., 65
Guzzi, U., 47

Ha, T., 57
Hagenmuller, F., 45
Halter, F., 57
Hanani, M., 70
Hanson, P.E., 44
Hanson, R.B., 5
Harling, H., 67
Hashmonai, M., 76
Heading, R.C., 59
Hedenborg, G., 60
Hellström, P.M., 35, 45, 60
Helm, J.F., 57
Helper, D.J., 77
Herman, A.G., 56
Herman, J.R., 53
Hewson, E.G., 68
Hillemeier, C., 78
Hoffman, A.D., 138
Hogan, W.J., 62, 105
Hollingsworth, J., 9
Hollwarth, M.E., 59
Holst, J.J., 67
Holzer, P., 144
Hoogmartens, J., 150
Hopert, R., 59
Hovendal, C., 67
Howard, P.J., 59
Huizinga, J.D., 64
Husebye, E., 60
Hutson, D., 63
Hyman, P.E., 29, 78

Ignaszewski, L.A., 53
Ito, T., 55
Itoh, Z., 57, 131
Iwanaga, Y., 57, 131

Jacob, P., 57
Jacobowitz, Y., 75
Jacoby, H.I., 52
Jager, L.P., 71
Janssens, J., 21, 45, 46
Janssens, W., 45
Jessen, H., 52
Jian, R., 60
Johansson, C., 35, 45
Johnson, A.G., 62
Joyce, J.M., 71
Jule, Y., 66
Junien, J.L., 48, 58, 66

Kahrilas, P.J., 57, 105
Kamal, N., 75
Kan, G., 69
Kandasamy, A., 73
Karasawa, T., 55
Karaus, M., 61
Katzka, D.A., 50
Katzlberger, F., 75

Kelly, C.E., 74
Kelly, K.A., 5
Kern, M.K., 105
Kimura, S., 78
Kingma, Y.J., 49, 51
Klein, A., 44
Knoflach, P., 75
Koch, K.L., 53
Koelbel, C.B., 29
Kondo, Y., 57
Konturek, S.J., 44
Kreis, S., 59
Kreulen, D.L., 77
Krevsky, B., 49
Kugi, A., 77
Kumar, D., 66

Lai, M., 61
Lam, H.G.Th., 69
Lang, I.M., 54
Langton, P., 74
Lash, J.A., 77
Lax, H., 70
Lee, K.Y., 78
Lefhalm, C., 61
Lemaire, M., 60
Lemann, M., 60
Lemon, M., 76
Lennon, V.A., 76
Li, Y.F., 61
Libby, G., 66
Liberge, M., 54
Libster, B., 49
Lichtenstein, G.R., 73
Linden, D., 68
Loeffler, R., 79
Loening-Baucke, V., 69
Logemann, J.A., 57
Lordal, M., 45
Luger, T., 75

MacGilchrist, A.J., 72
Madlag, N., 70
Malagelada, J.-R., 138
Malbert, C.H., 15
Malegelada, J.-R., 51
Manaka, H., 63
Manaka, Y., 63
Manara, L., 47
Mandrek, K., 59
Marzio, L., 45
Matthijs, G., 47, 150
Mattioli, S., 99
Mawe, G.M., 79
Mayer, E.A., 29, 80
McCallum, R.W., 62
McDonald, T.J., 65
McHale, N.G., 74
Messell, T., 67
Michetti, F., 48

Midtvedt, T., 60
Mikkelsen, H.B., 51
Milla, P.J., 53
Miller, L.J., 51
Miller, S.M., 79
Mittal, R.K., 46
Miyashita, N., 57
Mizrahi, M., 73
Mizumoto, A., 57, 131
Monroy, M., 79
Morad, M., 50
Muir, T.C., 58

Nagahama, H., 63
Neri, M., 74
Neuhaus, H., 45
Neveux, P., 49
Nicolov, S., 60
Niederau, C., 61
Nielubowicz, W.J., 49
Nilsson, I., 60
Niznik, G., 68
Norell, M., 74
Nowak, T.V., 56

Orkin, B.A., 5
Ott, D.J., 68
Otterson, M.F., 50, 70
Ouyang, A., 72
Ovist, N., 67

Parkman, H.P., 73, 76
Pascaud, X., 48, 66
Pedersen, S.A., 67
Peeters, T.L., 46, 47, 150
Pelckmans, P.A., 56
Percy, W.H., 75
Perrault, J., 138
Pertl, Ch., 144
Peters, S., 51
Phillips, S.F., 74, 75
Pieramico, O., 45
Pilot, M.A., 65
Pinotti, R., 46
Piretta, L., 48
Pons, L., 58
Pryde, A., 59
Publicover, N.G., 74

Qin, X.Y., 65

Raffa, R.R., 52
Rambaud, J.C., 60
Rampart, M., 56
Rasmussen, I., 67
Raybould, H.E., 50
Read, N.W., 1
Reda, E., 49
Reddy, S.N., 50, 69, 80
Ren, J., 62
Reynolds, J.C., 73
Rhim, B.Y., 78
Richter, J.E., 67, 68
Riecken, E. O., 59
Rodriques, A.M., 68
Rollo, V., 46
Root, D., 29
Rothstein, R.D., 72
Ruckebusch, Y., 15, 49
Ryan, J.P., 73

Sabourin, P.J., 51
Sanders, K.M., 73, 74
Sarna, S.K., 1, 50, 54, 57, 70, 90
Sarr, M.G., 51, 68, 69
Sarti, P., 46
Sato, H., 63
Schemann, M., 54, 56
Scheurer, U., 57
Schirmer, B., 66
Schneider, C., 75, 77
Schulze-Delrieu, 56
Schuster, M.M., 75
Schuurkes, J.A.J., 46
Scott, M., 65
Sears, V., 67
Seggerman, R.E., 61
Serio, R., 64
Severi, C., 48
Shaffer, E., 70
Shah, V., 57
Shaker, R., 62
Shannon, S., 9
Sharpnack, D., 72
Shea-Donohue, T., 72
Shirazi, S., 56
Siegle, M.S., 54
Sillin, L., 79
Sinar, D.R., 71
Sjogren, R., 72
Sluss, J., 46, 62
Smith, T.K., 71
Smolen, J., 75
Smout, A.J.P.M., 69, 122
Smythe, A., 62
Snape, W.J. Jr., 29, 69, 78
Sninsky, C.A., 53
Soergel, K.H., 1
Solomon, T., 73
Sperry, N., 53
Springfels, S., 78
Stacher, G., 75, 77
Stapelfeldt, W.H., 76
Staumont, G., 58
Steensrud, M., 54
Steiner, G., 77
Steiner-Mittelbach, G., 75
Stern, R. M., 53
Strieff, R.R., 53
Stubbs, C.C., 62
Stubbs, J.B., 62
Summy-Long, J., 53
Svenberg, T., 60
Sytnik, B., 80
Szewczak, S., 78
Szurszewski, J.H., 68, 69, 76, 79

Tache, Y., 50, 80
Takahira, H., 72
Tamura, K., 72
Tanaka, M., 51
Tappeiner, G., 75
Taylor, G.S., 115
Telander, R.L., 76
Telford, G.L., 70
Theodorou, V., 85
Theodorsson, E., 60
Thomason, D.B., 61
Thompson, H.H., 65
Thompson, P., 66
Thor, P., 44
Thuneberg, L., 51, 52
Tijskens, G., 21
Tollstrom, T., 60
Tomomasa, T., 78
Tooker, J., 78
Torsoli, A., 48
Tosoni, M., 48
Tottrup, A., 55
Tremblay, L., 68
Turkelson, C., 73

Uray, E., 59

Valdez, D.T., 68
Valenzuela, G., 62
Valori, R.M., 76
van Blankenstein, M., 122
van de Merwe, J.P., 122
Van Den Brink, E.W., 46
Van Der Schaar, M.W.G., 71
van der Schee, E.J., 122
Van Deventer, G., 80
Van Maercke, Y.M., 56
Van Neuten, J.M., 46
Van Rossum, J.M., 46
Vantrappen, G., 21, 45, 46, 47, 150
Varner, D.E., 70
Vaxman, F., 44
Verbeuren, T.J., 56
Vermillion, D.L., 65
Vesselinova-Jenkins, C.K., 66
Virina, M.A., 79
Vogalis, F., 115

Wade, P.R., 79
Waldhausen, J., 66
Wallstein, U., 61
Wang, M.B., 73

Ward, S.M., 73, 74
Weems, W.A., 61
Weisbrodt, N.W., 61
Weisbruch, J.P., 56
Wenger, F., 57
Whitehead, W.E., 75
Wiesnagrotzki, S., 77
Willemse, P., 46
Williams, C.L., 76
Williams, N.S., 65
Williams, R., 29
Wingate, D.L., 66
Wolf, G., 144
Wood, J.D., 72, 77
Wu, W.C., 68

Xie, Y., 69

Yamanaka, K., 76
Yau, W.M., 67
Yoshida, N., 55, 57
Youther, M.L., 67
Yuan, C.S., 71

Zamir, O., 70
Zimmerman, K., 72

Index to Volume 2: Subject

Acetylcholine, 138(ab), 172–174
Acetylcystine, 60–64
Achalasia, 287–294
Acid exposure, esophageal, 117–120
Acoustic stress, 258–262
Actin, 209–214
Actomyosin, esophageal muscle contraction and, 209–214
Adenosine, intestinal myoelectric activity and, 121–126
Adenosine analogs, intestinal myoelectric activity and, 121–126
Adenosine 5′-triphosphate, 147(ab)
Adrenalectomy, 265
Adrenergic agonists, selective, 133(ab)
Adrenergic antagonists, selective
  gastric tone in rats and, 133(ab)
  ileal brake mechanism and, 135(ab)
Adrenoceptor antagonists, selective
  motor activity control and transmural potential differences in rabbit ileum and, 47–51
α_2-Adrenoceptors, 1–9
Alcoholism
  esophageal motility disorders of, 146(ab), 162(ab)
  gastrointestinal transit disorders of, 162(ab)
Alimentary vagal afferents, characterization of, 142(ab)
Anal manometry, of fecal continence, 132(ab)
Anal sphincter
  innervation of, 140(ab)
  spontaneous relaxation of, 140(ab)
Anorectal motility, 144(ab)
Anorexia, with chronic renal failure, 156(ab)
Anti-anginal therapy, esophageal chest pain and, 134(ab)
Anticholinesterase activity, 273–279
Antroduodenal motility
  cisapride and, 137(ab)
  secretin and, 148(ab)
Apomorphine, and gastric tone and duodenal motility during vomiting, 1–9
Asperlicin, 169–175
Atropine, 281–285

Bacterial overgrowth, in chronic diarrhea, 180–182
Balloon distention, 90–94, 138(ab)
Benzamides, 157(ab)
Biofeedback, for fecal incotinence, 136(ab)
Blood pressure, ranitidine and, 273–279
Bombesin, 154(ab)
Brain-gut interactions, 1–9
Breath hydrogen technique, 194–200
Bretylium, 265–271
BRL 24924, simulation of canine gastric motility, 281–285
BRL 43694 (granisetron), 135(ab), 281–285

Caerulein, 145(ab), 172–174
Calcitonin gene-related peptide, 143(ab)
Calcium antagonists, 53–58
Calcium channel, 53–58
Calcium channel blockers, colonic transit time in humans and, 176–178
Campylobacter pylori infection, 161(ab)
Capsaicin, 265–271
CCK. *See* Cholecystokinin
CCK-8. *See* Cholecystokinin octapeptide
Celiac ganglionic neurons, 152(ab)
Chest pain, noncardiac
  ambulatory pH monitoring, 231–238
  from anti-anginal therapy, 134(ab)
  diagnosis of, 138(ab)
  esophageal air and, 142(ab)
  of gastroesophageal reflux, 140(ab)
  provocation testing and, 146(ab)
  in suspected myocardial ischemia, 153(ab)
Children
  with chronic renal failure, anorexia and, 156(ab)
  with cystic fibrosis, gastroesophageal reflux patterns in, 137(ab)
  with gastroesophageal reflux, LES function in, 137(ab)
Cholecystectomy, postoperative bile flow, 157(ab)
Cholecystokinin agonists, effects on contractile and myolectric activities, 169–175
Cholecystokinin antagonists, effects on contractile and myolectric activities, 169–175
Cholecystokinin (CCK)
  duodenal motility and, 40–45
  endogenous, ascending exitatory neural pathway of rat ileum and, 130(ab)
  esophageal motility and, 148(ab)
  gallbladder motility and, 40–45
  inhibition of gastric emptying and gastric secretion, 150(ab)
Cholecystokinin octapeptide (CCK-8)
  colon muscle inhibition and, 149(ab)
  MMC inhibition, 252–253
  pyloric contractions and, 141(ab)
  ventromedial hypothalamus neurons and, 150(ab)
Cholinergic antagonists, 23–29
Cholinergic nerves, 23–29
Chronic renal failure, anorexia and vomiting in, 156(ab)
Cimetidine, anticholinesterase activity, 273–279
Cinitapride, 141(ab)
Cisapride, 137(ab), 159(ab)
Codeine, 161(ab)
Cold stress, esophageal sphincter motor function and, 155(ab)
Colitis, colonic transit in, 156(ab)
Collagen, esophageal muscle contraction and, 209–214
Colon
  CCK agonists and, 169–175
  CCK antagonists and, 169–175
  circular muscle of, 149(ab), 160(ab), 163(ab)
  contractile frequency patterns of, 73–77
  propagation of contractions and transport in, 132(ab)
Colon motility
  α-adrenergic influences, 159(ab)
  basal, loxiglumide and, 146(ab)
  long duration stress and, 163(ab)
  measurement with transit time, 155(ab)
  in naloxone-precipitated opiate withdrawal, 90–94
  nitrendine binding and, 53–58
  in opiate addiction, 90–94
  serotonin and, 160(ab)
Colon motor activity
  exercise and, 137(ab)
  in feeding, 150(ab)
  psychic stress-induced, sigma ligands and, 143(ab)
  vagal cryo-interruption and, 138(ab)
Colon myocytes, nitrendipine binding, 53–58
Colon transit time
  calcium channel blockers and, 176–178
  in diarrhea, 148(ab)
  in experimental colitis in rats, 156(ab)
  measured with colon motility, 155(ab)
  peripheral and central motor and secretory components in, 161(ab)
Colorectal motility, in paraplegia, 12–16
Composite rhythms, 109–115
Computer-aided manometry, esophageal, 163(ab), 216–222
Computer analysis, of gastro-intestinal contractions, 147(ab)
Computer assisted diagnosis, in esophageal motor disorders, 145(ab)
Computer modeling, of ECA and ERA, 109–115
Constipation, chronic
  fluid intake and physical activity in, 149(ab)
  squatting postion and, 144
Contractions, muscular. *See also under specific muscles*

acetylcholine-induced, H_2-receptor antagonists and, 273–279
carbachol-induced, 265–271
cecal origin, 224–228
cholecystokinin agonists and, 169–175
cholecystokinin antagonists and, 169–175
Control potentials, 104–108
Corticotropin-releasing factor (CRF), 265–271
Cortisol release, antagonism of, 258–262
CR1392, 169–175
CR1409, 169–175
CR1505, 169–175
CY 208–243, motor activities of, 158(ab)
Cyclic nucleotides, smooth muscle relaxation and, 65–71
Cystic fibrosis, gastroesophageal reflux patterns in, 137(ab)

Defecation
facilitation by squatting, 144(ab)
rectal content volume and, 148(ab)
Diabetes mellitus
with fecal incontinence, pelvic floor neuropathy and, 155(ab)
gastric fundus activity and, 150(ab)
orocecal transit and, 194–200
Diaphragm electromyogram, 184–188
Diarrhea
bacterial overgrowth of, 180–182
transit time, colonic motor activity and, 148(ab)
Digestive states, plasma motilin and, 240–245
Distal ileum, perendoscopic manometry of, 136(ab)
Dogs
contractile and myoelectric activity, 169–175
descending colon, 131(ab)
histamine Hreceptor antagonists, anticholinesterase activity of, 273–279
intestinal motility patterns, 31–38
plasma cortisol release, 258–262
stress-induced gastric motor alteration, 258–262
Dopamine, 140(ab)
Dopamine receptors, in vomiting, 1–9
Duodenogastric reflux, 136(ab)
Duodenum
contractions, inhibitory innervation and, 1551(ab)
motility, cholecystokinin and, 40–45
Dyspepsia, idiopathic, 137(ab)

Efferent stimulation, colonic motor activity and, 138(ab)
Electrical control activity, modeling of, 109–115
Electrical response activity, modeling of, 109–115
Electric control activity, 104–108
Electromyography
diaphragm, 184–188
of fecal continence, 132
in gastroparesis, 104–108
Emphysema, pulmonary, 152(ab)
Endoscopic sclerotherapy, esophageal motility and, 96–103
Enprostil, 161(ab)
Enteric nerves, 247–255
Equine ileocecal sphincter, 224–228
Erythromycin
gastric motor activity and, 162(ab)
LES function and esophageal body contractility, 146(ab)
Esophageal acid clearance
physiological variations of, 134(ab)
in reflux esophagitis, 79–88
Esophageal acid exposure, reflux symptomatology and, 231–238
Esophageal air, non-cardiac chest pain and, 142(ab)
Esophageal body
in phase III of MMC, 130(ab)
striated muscle, oxidative capacity of, 209–214
Esophageal chest pain. *See* Chest pain, noncardiac
Esophageal contractions
secondary, in REM sleep, 136(ab)
sleep-stage dependency of, 131(ab)
Esophageal manometry
balloon sensor for, 151(ab)
computer-aided, 163(ab), 216–222
of lower esophageal sphincter pressure, 23–29
of non-cardiac chest pain, 146(ab)
Esophageal motility
after sclerotherapy, 96–103
cholecystokinin and, 148(ab)
in pulmonary emphysema, 152(ab)
Esophageal motility disorders
in alcoholism, 146(ab), 162(ab)
detection by standardized rice barium meal, 160(ab)
Esophageal motor disorders
computer assisted diagnosis, 145(ab)
globus sensation and, 152(ab)
outcome of reflux esophagitis and, 131(ab)
Esophageal muscle
biochemistry of, 209–214
movements, in partial obstruction, 159(ab)
Esophageal relaxation, by benzamides, 157(ab)
Esophageal sphincter motor function, cold stress and, 155(ab)
Esophageal transit, pharyngeal pump and, 149(ab)
Esophageal varices, endoscopic sclerotherapy of, 96–103
Esophagitis, gastrointestinal reflux and, 164(ab)
Esophagogastric junction, quantification of resistance to flow, 287–294
Esophagus, motor responses to mechanoreceptor stimulus, 163(ab)
Exercise, colonic motor activity and, 137(ab)

Familial visceral myopathy, 189–192
Famotidine, anticholinesterase activity, 273–279
Fats, dietary
gastric motility and, 160(ab)
gastroesophageal reflux and, 131(ab)
Fecal continence, 132(ab)
Fecal incontinence, biofeedback training for, 136(ab)
Fedotozin, 258–262
Ferret, gastric corpus compliance in, 143(ab)
Fiber, dietary, 164(ab)
Fluid intake, with dietary fiber for stool regulation, 164(ab)
Food type, gastric emptying and, 142(ab)

Galanin
contractile activity and, 143(ab)
ileum smooth muscle contractions and, 138(ab)
luminal cross-sectional area in perfused pig ileum and, 143(ab)
Gallbladder
contraction, exogenous and endogenous stimulation of, 142(ab)
spontaneous contractile activity in, 151(ab)
Gallbladder motility
cholecystokinin and, 40–45
in gallstone patients, CCK and, 154(ab)
Gallstones, orocecal transit and, 194–200
Ganglionectomy, celiac/superior mesenteric, 265–271
Gastrectomy, total, 132(ab)
Gastric acid secretion, cholecystokinin and, 150(ab)
Gastric antrum
contractions, STIL 2875 and, 152(ab)
distension, 157(ab)
Gastric cancer, intestinal reconstruction, 132(ab)
Gastric contractions, visualization and characterization by radionuclide technique, 162(ab)

Gastric corpus compliance, vasoactive intestinal polypeptide and, 143(ab)
Gastric cyclic motor activity, control mechanisms, 144(ab)
Gastric emptying
in acute pancreatitis, 139(ab)
cholecystokinin and, 150(ab)
CRF-induced delay, 265–271
disorders of, peristaltic function in, 130(ab)
intraduodenal acid and, 202–207
JO 1754, 154(ab)
modulation by type of meal and immobilization stress, 142(ab)
regulation by hyperglycemia, 139(ab)
stress and, 18–21
Gastric fundus, motor activity in diabetes, 150(ab)
Gastric inhibitory polypeptide, gastric emptying and, 139(ab)
Gastric motility
acoustic-stress induced alterations of, 258–262
dietary fat intake and, 160(ab)
impedence gastrography of, 135(ab)
inhibition of, 265–271
serotonin and, 133(ab)
simulation of, 281–285
Gastric motor activity, 273–279
Gastric motor response, to solid and liquid meals, 157(ab)
Gastric myoelectric activity, in gastroparesis, 104–108
Gastric myoelectrical and impedance signals, bedside system for cutanous recording and analysis, 135(ab)
Gastric tone
duodenal motor events after vomiting and, 1–9
pain-induced inhibition of, 133(ab)
Gastric ulcer, orocecal transit and, 194–200
Gastrocolonic response, loxiglumide and, 146(ab)
Gastroesophageal competence, 287–294
Gastroesophageal reflux
chest pain, assessment of, 140(ab)
in cystic fibrosis, 137(ab)
dietary fat and, 131(ab)
distal esophageal acid exposure and, 231–238
multiple impedancemetry, 141(ab)
spontaneous, in reflux esophagitis, 79–88
symptom-reflux association, 231–238
upper esophageal sphincter pressure and, 117–120
Gastrointestinal contractions, computer analysis of, 147(ab)
Gastrointestinal hormones, 240–245
Gastrointestinal motility
calcium channel blockers and, 176–178
in gastroparesis, 104–108
pancreatic disease and, 151(ab)
plasma motilin variations and, 240–245
postoperative restitution, 145(ab)
Gastrointestinal reflux, esophagitis and, 164(ab)
Gastrointestinal tract, bombesin and, 154(ab)
Gastrointestinal transit disorders, in alcoholism, 162(ab)
Gastroparesis, gastric myoelectric activity in, 104–108
Globus sensation, esophageal motor disorders and, 152(ab)
Glyceroltrinitrate, 157(ab)
GN25, 153(ab)
Granisetron (BRL 43694), 135 (ab), 281–285
Guinea pigs
contractile and myoelectric activity of, 169–175
gastric antrum activity, norepinephrine and, 161(ab)
gastric fundus, acetylcholine-activation of, 138(ab)
myenteric plexus-longitudinal muscle preparations, 141(ab)

H_2-antagonists, interdigestive antroduodenal motility and, 134(ab)
Heidenhain pouch preparations, 281–285
Hexamethonium, 265–271, 281–285
Histamine, 172
Histamine H_2-receptor antagonists, 273–279
Histamine-H3-receptors, 159(ab)
Hormonal control, 247–255
5-HT_3 receptor antagonist, ileal brake mechanism and, 135(ab)
Hydrochloric acid, intraduodenal, gastric emptying and, 202–207
5-Hydroxytryptamine
canine intestinal motility patterns and, 31–38
motility enhancing effects of, 159(ab)
vagal afferent responses and, 133(ab)
5-Hydroxytryptamine receptors, antagonism of, 281–285
Hypercortisolemia, 258
Hyperglycemia, regulation of gastric emptying, 139(ab)
Hyperpolarizations, gastric motility modifications and, 152(ab)

Ileal brake mechanism, 135(ab), 158(ab)
Ileocecal flow, 194–200
Ileocecal sphincter
equine, 224–228
perendoscopic manometry of, 136(ab)
tonic activity of, 155(ab)
Ileum smooth muscle contraction, galanin-induced, 138(ab)
Ileus, postoperative, 134(ab)
Impedancemetry, multiple, 141(ab)
Impedence gastrography, 135(ab)
Indomethacin, 144(ab)
Interdigestive state
antro-duodenal motility, Hantagonists and, 134(ab)
BRL 244924 and, 281–285
plasma motilin variations, 240–245
Interrelated rhythmic activities, 109–115
Intestinal adaptation, 60–64
Intestinal motility
adrenergic control of, 47–51
alteration after roux-en-y-reconstruction, 158(ab)
in familial visceral myopathy, 189–192
free radical production in, 141(ab)
gastric tone variations and, 1–9
5-hydroxytryptamine and, 31–38
neurotensin and, 140(ab)
Intestinal myoelectric activity
adenosine analogues and, 121–126
adenosine and, 121–126
Intestinal propulsion, 121–126
Intestinal pseudo-obstruction, 189–192
Intestinal transit
acetylcysteine and, 60–64
regulation with dietary fiber and fluids, 164(ab)
Intraduodenal acid, gastric emptying and, 202–207
Intraesophageal electrode position, 184–188
Intraluminal pressure
corticotropin-releasing factor and, 265–271
at equine ileocecal junction, 224–228
Intrathoracic stomach, as esophageal replacement, 153(ab)
Irritable bowel syndrome, orocecal transit and, 194–200

Jejunal limb, contractile activity of, 132(ab)
Jejunal manometry, in familial visceral myopathy, 190–192
JO 1754, 154(ab)

Large intestine motility
loperamide and, 147(ab)
lopoxyde and, 147(ab)
LES. *See* Lower esophageal sphincter
Leukotrienes D in experimental colitis, 156(ab)
Lipid-induced LESP, 153(ab)

Loperamide, small and large intestine motility and, 147(ab)
Lopoxyde, small and large intestine motility and, 147(ab)
Lower esophageal sphincter (LES)
in gastroesophageal reflux disease, 137(ab)
intraesophageal electrode position and, 184–188
oxidative capacity of, 209–214
in phase III of MMC, 130(ab)
resistance to flow, quantification of, 287–294
Lower esophageal sphincter pressure
GN25 and, 153(ab)
interdigestive, neural contribution to, 23–29
in pulmonary emphysema after theophylline, 152(ab)
Loxiglumide
basal colonic motility and, 146(ab)
gastrocolonic response and, 146(ab)

Manometry
anal, 132(ab)
of colon contractile frequency patterns, 73–77
computerized recording, 163(ab)
esophageal, computer-aided, 216–222
of esophageal acid exposure on UES pressure, 117–120
perendoscopic, in distal ileum and ileo-cecal junction, 136(ab)
small intestinal, in familial visceral myopathies, 190–192
Mesenteric ischemia, 141(ab)
Metabolic disorders, free radical production in, 141(ab)
Methadone, colon motility and, 90–94
Mice, stress-induced gastric emptying and, 18–21
Migrating motor complex (MMC)
in chronic diarrhea, 180–182
in gallbladder and duodenal motility, 40–45
inhibition of, 258–262
interdigestive and postprandial myoelectric patterns and, 247–255
intestinal motility patterns and, 31–38
jejunal, initiation by oral codeine, 161(ab)
lower esophageal sphincter pressure and, 23–29
modulation of, 133(ab)
phase III, 130(ab)
plasma motlin and, 240–245
Modeling of colonic electrical activity, synthesized relaxation oscillator and, 109–115
Monkeys, colonic motor activity in, 138(ab)
Morphine
duodenal tone during vomiting and, 1–9
gastric tone during vomiting and, 1–9
in reservoir function of dog descending colon, 131(ab)
Motilin
CCK antagonists and, 172
gallbladder motility and, 40–45
plasma levels during interdigestive and digestive states, 240–245
Motilin receptors, in rabbit colon, 139(ab)
Muscarinic receptor subtypes, 156(ab)
Muscle, isolated, 169–175
Muscle weight, 60–64
Muscularis mucosae ,in jejunum in situ, 158(ab)
Myoelectric activity
cholecystokinin agonists and, 169–175
cholecystokinin antagonists and, 169–175
intestinal, adenosine and adenosine analogues and, 121–126
of muscularis mucosae in jejunum in situ, 158(ab)
Myoneural continuity, 247–255
Myosin, 209–214

Naloxone
gastric emptying and, 265–271
gastric motor activity suppression, 258–262
opiate withdrawal, colon motility in, 90–94
Neural control, 247–255
Neurokinin analogs, 130(ab)
Neurokinins, 149(ab)
Neuropeptide Y, 147(ab)
Neurotransmitter release, in gastric fundus of diabetic rats, 150(ab)
Nicotinic synapse, 265–271
Nifedipine, for nutcracker esophagus, 154(ab)
Nitrendipine, binding to rabbit colonic smooth muscle, 53–58
Nocloprost, 150(ab)
Noradrenergic nerve systems, in modulation of rat MMC, 133(ab)
Norepinephrine, in myenteric plexus of guinea-pig gastric antrum, 161(ab)
Nutcracker esophagus, nifedipine for, 154(ab)

Opiate addiction, colon motility in, 90–94
Opiate peptides, in reservoir function of dog descending colon, 131(ab)
Opioid receptors, in vomiting, 1–9
Opioids, 258–262

Opossum
esophageal muscles, 209–214
lower esophageal sphincter pressure in, 23–29
Orocecal transit time, 194–200

Pancreatic disease, gastrointestinal motility and, 151(ab)
Pancreatitis, delayed gastric emptying in, 139(ab)
Paraplegia, motility effects of electrical anterior sacral nerve root stimluation, 12–16
Pelvic floor neuropathy, in diabetes with fecal incontinence, 155(ab)
Pentagastrin, inhibition of MMC, 252–253
Perstalsis, ultrasound evaluation of, 130(ab)
pH
ambulatory monitoring of, in suspected gastroesophageal reflux, 231–238
of distal esophagus after sclerotherapy, 96–103
esophageal acid clearance and, 134(ab)
of gastrointestinal refluxate, 164(ab)
of intra-gastric concentration, in duodenogastric reflux, 136(ab)
Pharyngeal pump, esophageal transit and, 149(ab)
Phentolamine, 281–285
Pig ileum
calcitonin gene-related peptide and, 143(ab)
galanin and, 143(ab)
Pinaverium bromide, 176–178
Pneumatic resistometer, 287–294
Postprandial period
breath hydrogen excretion during, 194–200
intestinal motility patterns, 31–38
motility, 247–255
Proglumide, 169–175
Propranolol, 281–285
Prostaglandin E_2 163(ab)
Prostaglandin E_2 analogs, 150(ab), 161(ab)
Prostaglandin synthesis, 144(ab)
Provocation testing, in non-cardiac chest pain, 138(ab), 146(ab)
Pylorus
adrenergic control of interdigestive and digestive motility and, 145(ab)
contractions, cholecystokinin octapeptide and, 141(ab)
motility, duodenal acid and, 202–207

Rabbit colon
motilin receptors of, 139(ab)
proximal, motility of, 156(ab)

Rabbit ileum, motor activity and transmural potential differences in, 47–51
Radionuclide binding, to rabbit colonic smooth muscle, 53–58
Ranitidine, anticholinesterase activity, 273–279
Rats
  electric rhythm, sodium channel blockers and, 132(ab)
  gastric tone in, 133(ab)
  ileal brake mechanism, 135(ab)
  ileum, endogenous CCK and, 130(ab)
  inhibition of gastric motor function, 265–271
  intestinal myoelectric activity, 121–126
  small intestine activity, neurokinin analogues and, 130(ab)
  stress-induced gastric emptying and, 18–21
Receptors, serotonin, 141(ab), 159(ab)
Rectal content volume, effort of defecation and, 148(ab)
Rectum resection, low anterior, anorectal motility, 144(ab)
Reflux esophagitis
  esophageal acid clearance in, 79–88
  outcome, esophageal motor disorders and, 131(ab)
  spontaneous gastroesophageal reflex in, 79–88
Regulatory peptide, 240–245
Relaxation oscillators, synthetic, 109–115
Rice barium meal, standardized, 160(ab)
Roux-en-y-reconstruction, intestinal motility alterations of, 158(ab)

Sacral anterior root stimulators, motility effects, 12–16
Sclerotherapy, esophageal motility and, 96–103
Secretin
  antroduodenal motility and, 148(ab)
  gastroduodenal motility stimulation, mental stress and, 145(ab)
Serotonin, differential effects on canine colonic motility, 160(ab)
Serotonin receptors, 141(ab), 159(ab)
Sleep, REM, secondary esophageal contractions in, 136(ab)
Sleep-stage dependency, of esophageal contractile activity, 131(ab)
Slow depolarizations, gastric motility modifications and, 152(ab)
Slow waves, 104–108
Small bowel motor activity, bacterial overgrowth and, 180–182
Small intestine, 47–51
Small intestine bypass, intestinal adaptation, acetylcystine and, 60–64
Small intestine motility
  indomethacin and, 144(ab)
  loperamide and, 147(ab)
  lopoxyde and, 147(ab)
Smooth muscle
  esophageal body, oxidative capacity of, 209–214
  gastric, 265–271
  relaxation, cyclic neucleotides and, 60–64
Sodium, intra-gastric concentration in duodenogastric reflux, 136(ab)
Sodium channel blockers, 132(ab)
Species differences, in stress-induced gastric emptying, 18–21
ST91, effect on gastric tone and duodenal motility during vomiting, 1–9
STIL 2875(ab)
Stress
  gastric emptying and, 18–21, 142(ab)
  gastric motor alteration induction, 258–262
  gut motor function in rat and, 156(ab)
  long duration, effect on colonic motility in rats, 163(ab)
  mental, 145(ab)
Substance P, 172
Succinate dehydrogenase, opossum esophageal muscles and, 209–214
Sympathetic nervous system, longitudinal smooth muscle activity and, 47–51

Tachyenteria, 153(ab)
Tetrodotoxind, 265–271
Theophylline, 152(ab)
Transmural potential differences, adrenoceptor antagonists and, 47–51

Ultrasound evaluation, of perstalsis, 130(ab)
Upper esophageal sphincter pressure, esophageal acid exposure and, 117–120

Vagal adrenergic reflexes, pain-induced inhibition of gastric tone and, 133(ab)
Vagal afferent responses, 5-hydroxytryptamine and, 133(ab)
Vagal cryo-interruption, colonic motor activity and, 138(ab)
Vagal non-adrenergic reflexes, pain-induced inhibition of gastric tone, 133(ab)
Vagotomy
  bilateral truncal, 258–262
  subdiaphragmatic, 265–271
Vasoactive intestinal polypeptide (VIP)
  gastric corpus compliance in ferret and, 143(ab)
  spontaneous and electrically induced gastric contractions and, 147(ab)
Ventromedial hypothalamus, 150(ab)
VIP. *See* Vasoactive intestinal polypeptide
Vomiting
  in children with chronic renal failure, 156(ab)
  gastroduodenal motility during, 1–9

Index to Volume 2: Author

Ancona, E., 96
Anuras, J., 190
Anuras, S., 190
Arias, A., 287
Armstrong, D., 216
Arndorfer, R.C., 79
Azpiroz, F., 1

Barbara, L., 104
Bardakjian, B.L., 109
Barnette, M.S., 65
Barone, F.C., 65
Bassotti, G., 73
Battaglia, G., 96
Bauerfeind, P., 216
Belloso, R.M., 60
Bermudez, J., 281
Binnie, N.R., 12
Biskin, L.C., 60
Blank, E.L., 23
Blum, A.L., 216
Boivin, M., 240
Bortolotti, M., 104
Bowers, R.L., 209
Bozeman, T., 190
Brooner, R., 90
Brunelli, F., 104
Bucaneve, G., 73
Buéno, L., 18, 121, 258
Bumm, R., 216

Calam, J.E., 180
Chaussade, S., 176
Cheskin, L.J., 90
Costantini, M., 96
Couturier, D., 176
Creasey, G.H., 12
Cusumano, A., 96

Davidson, H.I., 31
Davison, J.S., 47
Dent, J., 79
De Ponte, F., 1
Diamant, N.E., 109
Dodds, W.J., 23, 47, 79
Dowling, R.H., 194
Dubinsky, W.P., 209

Dudrick, S.J., 60
Duenes, J.A., 247
Dunbar, A., 281

Edmond, P., 12
Emde, C., 216

Fallet, M., 176
Fargeas, M.J., 121
Fioramonti, J., 18, 121
Fisher, M.J., 184
Froguel, E., 176
Fudge, M., 65
Fujimura, M., 273

Gill, R.C., 180
Green, G.M., 60
Greenwood, B., 47
Grous, M., 65
Gué, M., 18, 258
Guerre, J., 176

Heading, R.C., 117, 231
Hogan, W.J., 23, 79
Holloway, R.H., 23
Houghton, L.A., 202
Howard, P.J., 194, 231
Hsu, C.T., 53
Hyman, P.E., 53

Itoh, Z., 273
Iwanaga, Y., 273

Jing, J., 53
Joslyn, A.F., 65
Junien, J.L., 258

Kahrilas, P.J., 79
Kao, H.W., 53
Karaus, M., 169
Kellow, J.E., 180
Kern, M.K., 79
Kerrigan, D.D., 202
Koelbel, C.B., 265
Kondo, Y., 273
Konturek, S.J., 40

Laskiewicz, J., 40
Layman, R.D., 23
Lazarus, C., 195

Macintyre, C.C.A., 117
Maczka, M., 40
Maisey, M.N., 194
Malagelada, J.-R., 1, 287
Malbert, C.H., 224
Manning, C.D., 65
Mayer, E.A., 265
Mearin, F., 287
Mittal, R.K., 184
Miyashita, N., 273
Mizumoto, A., 273
Morelli, A., 73

Niederau, C., 169

Ormsbee, H.S. III., 65

Pascaud, X., 258
Pelli, M.A., 73
Peracchia, A., 96
Pilot, M.-A., 31
Poitras, P., 240
Price, W.J., 65
Pryde, A., 117, 231

Raybould, H.E., 265
Raymond, M.C., 240
Read, N.W., 202
Riberdy, M., 240
Roche, H., 176
Roger, T., 224
Roveran, A., 96
Ruckebusch, Y., 224

Sanger, G.J., 281
Sarna, S.K., 23, 109
Sarr, M.G., 247
Sarti, P., 104
Schuster, M.M., 90
Scibetta, D., 96
Shabsin, H.S., 90
Smith, A.N., 12
Snape, W.J. Jr.
St-Pierre, S., 240

Taché, Y.
Thomforde, G.M., 1
Thompson, H.H., 31
Thompson, W.E., 65
Thor, P., 40
Tomomasa, T., 53
Trudel, L., 240
Turner, D.H., 281

Weisbrodt, N.W., 60, 209
Whitehead, W.E., 90
Wilson, J.A., 117
Wingate, D.L., 180

Yaksh, T.L., 1
Yoshida, N., 273

Zacchi, P., 287
Zaninotto, G., 96
Zinsmeister, A.R., 247